Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
2.450
-0.060 (-2.39%)
Aug 13, 2025, 4:00 PM - Market closed
IMDX Employees
As of December 31, 2024, Insight Molecular Diagnostics had 49 total employees, including 46 full-time and 3 part-time employees. The number of employees increased by 3 or 6.52% compared to the previous year.
Employees
49
Change (1Y)
3
Growth (1Y)
6.52%
Revenue / Employee
$86,878
Profits / Employee
-$1,294,224
Market Cap
70.12M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMDX News
- 2 days ago - IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - GlobeNewsWire
- 9 days ago - iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - GlobeNewsWire
- 14 days ago - IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients - GlobeNewsWire
- 16 days ago - iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025 - GlobeNewsWire
- 7 weeks ago - iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing - GlobeNewsWire
- 2 months ago - Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville - GlobeNewsWire
- 3 months ago - Medicare Boosts Reimbursement for Oncocyte's Flagship Technology - GlobeNewsWire
- 3 months ago - OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript - Seeking Alpha